In:
Annals of the Rheumatic Diseases, BMJ, Vol. 80, No. Suppl 1 ( 2021-06), p. 887.2-888
Abstract:
Severe and life threating COVID-19 pneumonia is often characterized by local and systemic immune-mediated hyperinflammation At the early disease stage activated monocytes are migrating to the lung and cause the typical opac infiltrates, which lead to an reduction of oxygen uptake. These pathophysiological observations and the fact that corticosteroids are so far the only drug, which has shown significant improvement, was the rationale use this combination anti-inflammatory drugs in severe Covid-19 disease. Interleukin (IL)-6 and IL-1 blockade alone, respectively showed contradictory results in severe COVID-19 pneumonia that might be related to the differences is patient populations (early vs. late stage) and to the fact that blockade of just one cytokine might be not sufficient against the cytokine storm. Objectives: Here we report results of an open-label treatment with a combination of an IL-6 receptor blocker tocilizumab and an IL-1 receptor antagonist anakinra in patients with early (up to 10 days since symptom onset) severe COVID-19 pneumonia with evidence of cytokine release. Methods: Adult patients with, according to World Health Organisation criteria, severe to critical COVID-19 infection associated pneumonia and cytokine release, requiring oxygen supplementation and evidence of rapid deterioration and decrease of oxygen saturation to ≤ 95% hospitalized between May 2020 and December 2020 were treated with tocilizumab 8 mg/ kg up to 800 mg intravenously and anakinra 100 to 300 mg for 3 to 5 days, starting at the same day. We excluded patients with a symptom duration of 〉 10 days, patients with evidence of bacterial infection, indicated by an elevated procalcitonin serum level, patients with severe pre-existing lung disease such as severe COPD or heart failure of 〉 II according to the NYHA classification and patients 〉 80 years. Laboratory parameters and chest CT were performed on initial presentation and one month after treatment. A semi-quantitative CT score was calculated based on the extent of lobar pneumonia involvement (0:0%; 1, 〈 5%; 2:5-25%; 3:26-50%; 4:51-75%; 5, 〉 75%; range 0-5; global score 0-25) for each time point. Results: 15 patients with severe to critical COVID-19 pneumonia and signs of cytokine release, mean age 55 (range 31-79) years, all male, with a mean symptom duration of 6 (range 4-10) days were treated. Mean oxygen saturation was 86% (range 76-95%) before initiating therapy. Mean ferritin was 1297 µg/l (range 347 – 2734), mean IL-6 112 ng/L (range 2.2 – 607.4) and CRP 82.4 mg/L (range 36.4 – 125). In all patients we were able to prevent them from intubation and mechanic ventilation, none of our patients died. Fife patients did not need to be referred to the intensive care unit at all, while 9 patients received noninvasive ventilation and high-flow nasal oxygen support. All patients showed typical imaging features of COVID-19 pneumonia at baseline (BL) according to the Radiological Society of North America (RSNA) chest CT classification system. The mean of the global chest CT severity score at BL was 13 (range 7-20) and decreased to 6 (range 0-16) within 1 month which corresponded to a mean reduction of 58%. Chronic fibrotic pulmonary changes were not seen in any patient at BL and after 1 month mild changes were observed in 6 patients. One patient experienced lower abdominal pain, urinary tract infection, gastrointestinal bleeding due to antrum ulcers Forrest III, in another patient atrial fibrillation, urinary tract infection and apoplexy were observed. Conclusion: In our case series, all patients treated with the combination tocilizumab and anakinra recovered fast and sustained without major infectious side effects, indicating that early interruption of cytocine release might be very effective and safe in preventing patients from mechanical ventilation, death and long-term damage. Image 1: Chest CT of a patient with active COVID-19 infection before and one month after treatment with a combination of tocilizumab and anakinra Disclosure of Interests: Hildrun Haibel Speakers bureau: Abbive, Novartis, Janssen, Pfizer, Roche, Consultant of: Janssen, Novartis, Roche, Janis Lucas Vahldiek: None declared, Stefan Angermair: None declared, Michael Schumann: None declared, Britta Siegmund Speakers bureau: Abbvie, CED Service GmbH, Falk, Ferring, Janssen, Novartis and Takeda as a representative of Charité – Universitätsmedizin Berlin, Consultant of: Abbvie, Arena, BMS, Boehringer, Celgene, Falk, Janssen, Lilly, Pfizer, Prometheus, Takeda representative of Charité – Universitätsmedizin Berlin, Grant/research support from: Pfizer, Denis Poddubnyy Speakers bureau: AbbVie, Bristol-Myers Squibb, Lilly, MSD, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Biocad, Gilead, GlaxoSmithKline, Eli Lilly, MSD, Novartis, Pfizer, Samsung Bioepis, and UCB, Grant/research support from: AbbVie, Eli Lilly, MSD, Novartis, and Pfizer, Thomas Schneider: None declared.
Type of Medium:
Online Resource
ISSN:
0003-4967
,
1468-2060
DOI:
10.1136/annrheumdis-2021-eular.2289
Language:
English
Publisher:
BMJ
Publication Date:
2021
detail.hit.zdb_id:
1481557-6
Bookmarklink
